19 April 2021
RECOVER was initiated as a means to directly tackle the COVID-19 pandemic by acting as PREPARE’s Mode 3 response, the highest response Mode. RECOVER is one of the 18 projects that the European Union has founded in response to the COVID-19 pandemic. It brings together leading scientists and research institutions to obtain crucial unknown information about the disease through clinical research in order to help the EU fight the virus and save patients’ lives. Now, it is time to look back on one year of RECOVER and what we have achieved so far.
The team consists of clinical researchers, epidemiologists, virologists, social scientists and laboratory technicians. They are carrying out research into specific topics that revolve around COVID-19. After one year, the research has already made such progress that there are more than 12.000 participants included in RECOVER and over 40 publications online. These publications focus on the virus, possible treatments as well as people’s attitudes towards various corona-related issues. In addition, 2 policy briefs have been published to influence and adjust policy on the basis of the experience gained. Another goal of the policy briefs was to provide guidance to adjust strategies for these topics in the Member States accordingly. These data have also been used by ECDC and WHO.
Progress of SOS-COVID
The RECOVER primary care observational study, SOS-COVID (work package 2, WP2), started in March 2020 and enrolled their first patients in the Netherlands on April 14th. The study aims to generate evidence about milder and/or undiagnosed SARS-CoV-2 infection, risk factors for a complicated course of disease, as well as to track the impact of the disease when managed outside the hospital. Patients were followed for 28 days to determine the course and impact of disease and complications (hospitalisation and death). An interim analysis showed that just over 10% of patients with a respiratory tract infection included in this study tested positive for SARS-CoV-2. The study aims to recruit 900 patients and analyses are planned for May and June 2021.
MERMAIDS ARI 2.0
The MERMAIDS ARI and MERMAIDS ARI 2.0 studies are part of the PREPARE consortium and work package 3 (WP3) of RECOVER, respectively. Since its reactivation, the MERMAIDS ARI study has included 336 patients at 30 sites. To enable broad geographical coverage in Europe, increased and targeted biological sampling, inclusion of children and enrichment of the cohort, the MERMAIDS ARI 2.0 study was set up. MERMAIDS ARI 2.0 has now enrolled just over 180 patients, including 169 COVID-19 patients, in 7 European countries. Another 3 countries are in the start-up process.
The REMAP-CAP study (work package 8, WP8) aims to determine the optimal treatment regimen for patients with severe community-acquired pneumonia (CAP). REMAP-CAP was designed to adapt and speed up research in the event of a pandemic. Due to the continued global spread of COVID-19, the REMAP-CAP pandemic strata were activated in March 2020. The study is currently active in 13 European countries with 205 sites. So far, 4,871 COVID-19 patients and 225 CAP patients have been randomized. In this first year, we have investigated 31 potential treatments for COVID. This has led to multiple platform conclusions, that have changed clinical care of hospitalized patients with COVID-19 immediately.
REMAP-CAP published its first results in JAMA on the effect of Hydrocortisone on organ-support free days in critically-ill COVID-19 patients, and in the New England Journal of Medicine showing treatment with Tocilizumab and Sarilumab improved outcomes in critically-ill COVID-19 patients receiving organ support in the ICU. We aim to continue to investigate repurposed as well as newly developed drugs, which can all be done in the trial. We also aim to collaborate with other EU and global groups to find the best treatments for patients fast.
RECOVER delivers a programme of cross cutting social science research that aims to strengthen the response to COVID-19 by generating insights around social and behavioural aspects related to COVID-19 and the public health response.
The Social Science team developed a survey tool for hospital health professionals in Europe to assess their perceptions of local infection prevention and control measures and their general wellbeing. Two rounds of surveys covered a total of 2,289 health professionals from 26 European countries. Data analysis was finalized and a manuscript was submitted for publication on 20 November 2020.
Research conducted in WP6 related to the needs and experience of household members informed discussions that fed into updated WHO guidelines on ‘Home care for patients with suspected or confirmed COVID-19 and management of their contacts’.
A survey in WP1 was conducted to analyse public perceptions on different aspects of the pandemic. In addition, the social sciences team of WP2 has conducted interviews with patients and general practitioners early in the pandemic in 8 European countries. The aim was to generate an understanding of their perspectives in receiving and providing primary care during the pandemic. All interviews have been finalized and data analysis is ongoing, with several manuscripts in preparation.
Read the full article on the clinical and laboratory network of COMBACTE in RECOVER